Moderna's cancer vaccine may be a 'major breakthrough', scientists say
A phase two clinical trial found the shot combined with immunotherapy drug Merck slashed the risk of melanoma returning by 44 percent compared to using the drug alone.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Clinical Trials | Health | Immunotherapy | Melanoma | Merck | Skin Cancer | Vaccines